All In Biotech

Drug Trial Radar · NCT04740476

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 20, 2021

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Stoke Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Conditions

  • Dravet Syndrome

Interventions

  • zorevunersen (STK-001)Drug

    zorevunersen drug product is an antisense oligonucleotide administered as an intrathecal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of multiple doses of zorevunersenTime frame: Screening (Day -1) until 6 months after multiple drug dosing

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco Medical Center

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Nicklaus Children's Hospital

    Miami, Florida

  • Florida Hospital for Children

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Michigan Medicine

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Comprehensive Epilepsy Center

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UT LeBonheur Pediatric Specialists, Inc.

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.